Just - Evotec Biologics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Just Biotherapeutics (Just.Bio) was a Seattle-based biotechnology company that integrated machine learning, scientific expertise and manufacturing to design, develop and produce protein drugs at lower cost. Its flagship J.POD platform used continuous, modular manufacturing to make biologics production faster and cheaper. Founded in 2014 by former Amgen scientists led by Jim Thomas, the company employed about 90 scientists and was backed by investors including the Bill & Melinda Gates Foundation. Evotec acquired it in 2019, and in December 2025 Evotec closed the sale of its Just - Evotec Biologics Toulouse site plus a technology license to Sandoz.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Just Biotherapeutics was founded in Seattle by former Amgen scientists led by James Thomas, with the mission of reducing the cost of protein drug development.
- Acquired by Evotec
German biotech company Evotec agreed to acquire Just Biotherapeutics for up to $90 million in cash, including milestone-based earn-outs, with an initial consideration of $60 million.
- Toulouse site sold to Sandoz
Evotec closed the sale of its Just - Evotec Biologics Toulouse site plus an indefinite license to its continuous manufacturing platform technology to Sandoz, with potential payments exceeding $650 million plus royalties.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.